Hospital Universitario de Valme -ko ikertzaileekin lankidetzan egindako argitalpenak (29)

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

2019

  1. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64

  2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888

  3. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

    PLoS ONE, Vol. 14, Núm. 8

2018

  1. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C

    Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948

  2. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis

    PLoS ONE, Vol. 13, Núm. 7

2017

  1. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

    Hepatology, Vol. 65, Núm. 6, pp. 1810-1822

2016

  1. Erratum: High-resolution hepatitis c virus subtyping using ns5b deep sequencing and phylogeny, an alternative to current methods (Journal of Clinical Microbiology (2015) 53:1 (219-226))

    Journal of Clinical Microbiology

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection

    Genes and Immunity, Vol. 16, Núm. 5, pp. 297-300

  3. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods

    Journal of Clinical Microbiology, Vol. 53, Núm. 1, pp. 219-226

2011

  1. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin

    American Journal of Gastroenterology, Vol. 106, Núm. 7, pp. 1246-1254

  2. La respuesta virológica al tratamiento con adefovir dipivoxil predice el desarrollo de resistencias a largo plazo en pacientes con hepatitis crónica B HBeAg negativo previamente no tratados

    Gastroenterologia y Hepatologia, Vol. 34, Núm. 2, pp. 69-74

2009

  1. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

    Hepatology, Vol. 50, Núm. 6, pp. 1702-1708

2008

  1. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C

    Journal of Hepatology, Vol. 48, Núm. 5, pp. 721-727

  2. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C

    Hepatology, Vol. 47, Núm. 3, pp. 810-816

  3. Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin

    Journal of Clinical Virology, Vol. 41, Núm. 4, pp. 264-269

2007

  1. Induction doses of interferon-α-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: A randomized trial

    Journal of Viral Hepatitis, Vol. 14, Núm. 2, pp. 89-95

  2. Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate

    Alimentary Pharmacology and Therapeutics, Vol. 25, Núm. 8, pp. 899-906